NASDAQ: ARWR

Arrowhead Pharmaceuticals (ARWR) Stock Analysis & Forecast

Nov 13 close

$47.78+0.63 (+1.3%)

Gekko Brief

AI summaryNov 9 close

This week's news centers on plozasiran, Arrowhead's RNAi therapy for severe hypertriglyceridemia. At the American Heart Association Scientific Sessions 2026, the company presented pooled data from the SHASTA-3 and SHASTA-4 trials showing sustained triglyceride reductions and a 78% reduction in acute pancreatitis events versus placebo, with a 91% reduction among patients with a history of the condition. Separately, Arrowhead refinanced its $400 million credit facility with Sixth Street, lowering borrowing costs and extending maturity to November 2031, and confirmed it will host its fiscal year-end results webcast alongside its upcoming earnings report.

Shares closed at $49.24, down 15.3% on the day and sitting well below both the 50-day average of $66.20 and the 200-day average of $71.46, with the 50-day below the 200-day. The one-month return stands at -21.5% and the three-month return at -44.8%, against a 52-week range of $37.06 to $95.49. The GekkoIndex reads 76.3, placing the stock in the Buying zone, while price sits 41.5% below Gekko Fair Value of $84.20.

Earnings are due 12 November 2026 after the close, just 81 days away, with options pricing an 8.1% move and a history of an average absolute reaction of 13.6% across prior reports, including a 43.7% move in November 2025. Seasonality over the next 20 trading days has averaged +9.2% across 5 years, rising in 2 of those years. No insider, Congress, or unusual options activity appears in the current windows, and consensus among 11 covering firms shows 10 buy ratings and 1 hold.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Arrowhead Pharmaceuticals price vs fair value

$78.84$47.78Nov ’25May ’26Nov ’26
Close $47.78200-day averageGekko Fair Value $78.84

Arrowhead Pharmaceuticals quick facts

Market cap
$6.75B
P/E ratio
—
Forward P/E
111.1
EPS, TTM
−$2.28
Revenue, TTM
$669.5M
Profit margin
-47.8%
Dividend yield
—
Beta
1.37
Volume
3.11M avg 1.96M
1-year return
+15.4%
Typical daily move
±6.7%
Typical 20-day move
±11.1%
50-day average
$63.32
200-day average
$71.09
Next earnings
Feb 4 after close
Shares outstanding
141.3M
52-week range
$37.06$95.49

Arrowhead Pharmaceuticals swing-trade checklist

Arrowhead Pharmaceuticals scores 5 supportive, 0 mixed and 1 headwind across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

5 supportive0 mixed1 headwind

  • Trendheadwind

    Below 50 and 200-day

    Close $47.78 is below the 50-day ($63.32) and 200-day ($71.09) averages, and the 50-day is below the 200-day.

    See the chart
  • GekkoIndexsupportive

    74.9, Buying

    Reading 74.9 is in the Buying zone.

    See the GekkoIndex
  • Fair valuesupportive

    39.4% below

    Price is 39.4% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 30 days: 1 unusual options signal.

    See smart money
  • Earnings risksupportive

    Reports in 81 days

    Next report Feb 4, 2027, 81 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +13.9% on average

    From this point in the calendar, the next 20 trading days averaged +13.9% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Arrowhead Pharmaceuticals stock chart and price history

Arrowhead Pharmaceuticals closed at $47.78 on Nov 13, 2026, +15.4% over the past year, inside a 52-week range of $37.06 to $95.49.

Close50-day average200-day averageVolume
Arrowhead Pharmaceuticals share price, past year, with 50-day and 200-day moving averages and volume$20$40$60$80DecJan 2026FebMarAprMayJunJulAugSepOctNov47.78

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−18.3%
3 months
−46.1%
6 months
−37.7%
1 year
+15.4%
The full ARWR chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ARWR in Gekko

Follow Arrowhead Pharmaceuticals through every session

Put ARWR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track ARWR in GekkoFree for 7 days. No credit card required.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals works on medicines for serious and hard-to-treat conditions, built around RNA interference technology that aims to switch off disease-causing genes. Its pipeline spans liver conditions linked to alpha-1 antitrypsin deficiency, high triglyceride levels, cholesterol-related targets, kidney cancer, lung and airway disorders, muscular dystrophy, gout and COVID-19-related pulmonary illness, with programs at stages ranging from early clinical trials to later-phase testing.

Much of its work is carried out through partnerships as well as internal research. It has agreements with Janssen Pharmaceuticals to jointly develop a set of RNAi candidates aimed at liver-related targets, and with Takeda Pharmaceuticals U.S.A. on another liver-disease therapeutic. It also contributes to programs such as a subcutaneous treatment for chronic hepatitis B, a candidate aimed at lowering apolipoprotein levels, and cardiovascular-focused therapies developed alongside outside partners, reflecting a model that combines its own science with outside collaboration.

Arrowhead Pharmaceuticals is based in Pasadena, California, and traces its founding back to 1989. Its shares are listed on the NASDAQ under the ticker ARWR.

Listed
NASDAQ
Sector
Health technology
Industry
Biotechnology
Website
arrowheadpharma.com

Arrowhead Pharmaceuticals GekkoIndex: the smart money zone

Arrowhead Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 74.9, in the Buying zone, up 9.1 points over five sessions.

010074.9Buying

Up 9.1 points over five sessions, from the Accumulation zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying (current zone)580.0%−0.3%−2.6%+9.4%
Accumulation229+0.3%+0.1%−0.1%+5.3%
Neutral378+1.1%+2.4%+5.6%+14.2%
Distribution36+2.5%+6.4%+12.3%+26.9%
Selling1Too few readings yet

Average ARWR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +2.9% over 20 days. Past behaviour doesn’t guarantee future results.

Buying zone: Smart money likely accumulating heavily. About the five zones →

See every daily GekkoIndex reading plotted over the ARWR price, zone by zone.Track ARWR in Gekko

Is Arrowhead Pharmaceuticals stock overvalued? Gekko Fair Value

Arrowhead Pharmaceuticals trades 39.4% below Gekko Fair Value of $78.84, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Arrowhead Pharmaceuticals shares are worth, recalculated every trading day.

$78.84

Gekko Fair Value, Nov 14, 2026

39.4% Undervalued

At the end of Aug 2026 the price was 18.3% below the estimate.

Gekko Fair ValueShare price, month end
$79$48Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open ARWR in Gekko

Arrowhead Pharmaceuticals insider and Congress trading

No open-market insider purchases were filed for Arrowhead Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for ARWR in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every ARWR insider filing, plotted on the chart in Gekko.Open ARWR in Gekko

Congress trades last 90 days

No trades in ARWR were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for ARWR, plotted on the chart in Gekko.Open ARWR in Gekko

Unusual options activity last 30 days

1signal, 97% of the flagged premium in calls.

Latest: Bullish flow on Nov 13, $516K in unusual premium.

Hedge funds and billionaires quarter ended Mar 31

1of the funds Gekko tracks holds ARWR.

0added0opened1trimmed1sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

Arrowhead Pharmaceuticals earnings: next date and track record

Arrowhead Pharmaceuticals reports on Feb 4, 2027, after the close (81 days away), and beat the EPS estimate in 3 of its last 8 reports.

3 of 8reports beat the EPS estimate
±9.1%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

−6.7%Feb ’25+17.3%May ’25+0.7%Aug ’25+30.4%Nov ’25−5.2%Feb ’26−8.2%May ’26+1.0%Aug ’26−3.2%Nov ’26

Last earnings call, Nov 12, 2026 AI summary

What they said
Arrowhead reported fiscal year 2026 results with REDEMPLO showing strong commercial traction: 950 new-to-brand prescriptions (63% QoQ growth), 640+ distinct prescribers, and 160M+ covered lives on payer formularies. The company submitted an sNDA on November 2, 2026 for severe hypertriglyceridemia (sHTG) indication under FDA's STAR priority review program. Management emphasized payer conversion remains a bottleneck but commercial infrastructure is progressing.
Guidance
Arrowhead targets a potential U.S. sHTG launch in Q2 2027, pending FDA approval under a 6-month STAR priority review. Management expects PDUFA date within 50 days of the November 2 submission. Revenue growth and profitability metrics will be key indicators post-sHTG launch.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 12, 2026−$3.04
est −$1.52
−100.0%$37.79M
est $61.18M
−38.2%−3.2%
Aug 4, 2026−$1.36
est −$1.23
−10.6%$75.25M
est $44.17M
+70.4%+1.0%
May 7, 2026−$0.93
est −$1.11
+16.2%$73.74M
est $73.84M
−0.1%−8.2%
Feb 5, 2026$0.22
est −$0.37
+159.5%$264.0M
est $213.9M
+23.4%−5.2%
Nov 25, 2025−$0.18
est −$0.11
−61.3%$256.5M
est $175.3M
+46.3%+30.4%
Aug 7, 2025−$1.26
est −$0.94
−34.0%$27.77M
est $154.1M
−82.0%+0.7%
May 12, 2025$2.75
est −$0.46
+697.8%$542.7M
est $116.3M
+366.8%+17.3%
Feb 10, 2025−$1.39
est −$0.72
−93.1%$2.50M
est $19.05M
−86.9%−6.7%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Arrowhead Pharmaceuticals stock forecast and analyst price targets

Analysts’ average 12-month price target for Arrowhead Pharmaceuticals is $107.71, +125.4% from the last close, from 12 firms rating the stock in the last 90 days.

$107.71consensus 12-month target, +125.4% from the last close
Low $74High $126
Buy11
Hold1
Sell0

Each firm’s latest rating in the last 90 days: 12 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 13UBSBuy, reiterated$109+128.1%
Nov 13Stifel NicolausBuy, maintained$96+100.9%
Nov 13RBC CapitalBuy, reiterated$100+109.3%
Nov 13Piper SandlerBuy, reiterated$126+163.7%
Nov 13Morgan StanleyBuy, maintained$106+121.9%
−2.6%average 20-day move after past Buying readings
+13.9%average move over the next 20 trading days in the last 5 years
±6.7%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Arrowhead Pharmaceuticals seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Arrowhead Pharmaceuticals averaged +13.9% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

+3.9%2021−0.7%2022−1.8%2023+2.1%2024+65.9%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−3.3%2 of 5
Next 10 trading days+12.0%4 of 5
Next 15 trading days+12.4%3 of 5
Next 20 trading days+13.9%3 of 5
Next 30 trading days+15.7%4 of 5

For scale, ARWR’s typical 20-trading-day move in either direction is about 11.1%.

Arrowhead Pharmaceuticals market cap and key statistics

Arrowhead Pharmaceuticals’s market cap is $6.75B and revenue of $669.5M over the last twelve months.

Valuation

Market cap
$6.75B
Forward P/E
111.1
EPS, TTM
−$2.28
Gekko Fair Value
$78.84

Trading

Volume
3.11M
Avg volume, 20 days
1.96M
52-week high
$95.49
52-week low
$37.06
Shares outstanding
141.3M

Financials

Revenue, TTM
$669.5M
Profit margin
-47.8%
Return on equity
-55.2%
Quarterly earnings growth, YoY
+9.8%

Risk and income

Beta
1.37
Typical daily move
±6.7%
Typical 20-day move
±11.1%

Arrowhead Pharmaceuticals peers

Arrowhead Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
UTHRUnited Therapeutics−0.4%Neutral11.2% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

Arrowhead Pharmaceuticals stock FAQ

What is Arrowhead Pharmaceuticals’s market cap?

Arrowhead Pharmaceuticals’s market cap is $6.75B at the Nov 13, 2026 close of $47.78, with 141.3M shares outstanding.

What is the Arrowhead Pharmaceuticals stock forecast?

The consensus analyst 12-month price target for Arrowhead Pharmaceuticals is $107.71, +125.4% from the last close. Of the 12 firms that rated the stock in the last 90 days, 11 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Arrowhead Pharmaceuticals stock overvalued or undervalued?

On Gekko’s estimate Arrowhead Pharmaceuticals is undervalued: the Nov 13, 2026 close of $47.78 is 39.4% below Gekko Fair Value of $78.84. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Arrowhead Pharmaceuticals report earnings next?

Arrowhead Pharmaceuticals is expected to report on Feb 4, 2027, after the market closes (81 days away). Analysts expect earnings of −$1.45 per share on revenue of $44.96M. Arrowhead Pharmaceuticals beat the earnings estimate in 3 of its last 8 reports, moving 9.1% on average across the report.

What is Arrowhead Pharmaceuticals’s 52-week high and low?

Arrowhead Pharmaceuticals’s 52-week high is $95.49 and its 52-week low is $37.06; it closed at $47.78 on Nov 13, 2026, +15.4% over the past year.

Is Arrowhead Pharmaceuticals stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (gekkoindex, fair value, smart money, earnings risk and seasonality) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in Arrowhead Pharmaceuticals?

Gekko flagged 1 unusual options signal in Arrowhead Pharmaceuticals over the last 30 days, with $501K of flagged premium in calls and $14K in puts. The latest, bullish flow, was on Nov 13, 2026 with $516K in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Arrowhead Pharmaceuticals the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.